TNF或EGFR抑制同等程度阻断AKI向CKD转化:依那西普治疗的机会
该研究在小鼠双侧肾缺血再灌注损伤或单侧输尿管梗阻模型中,比较TNF抑制与EGFR抑制对急性肾损伤向慢性肾脏病转化(AKI-to-CKD)的影响。结果显示两者均同等减少约25%的转化和纤维化,联合无额外获益;EGFR抑制通过减少肾脏TNF表达免疫细胞积聚降低TNF表达约50%,而TNF抑制不影响EGFR活化。作者结论认为AKI期间或之后短期使用抗TNF生物制剂可能有助于预防AKI-to-CKD转化。
要点
- TNF抑制或EGFR抑制均同等减少小鼠AKI-to-CKD转化和纤维化约25%,联合无额外效果。
- EGFR抑制使肾脏TNF表达降低约50%,主要减少早期AKI肾脏中表达TNF的免疫细胞积聚。
- TNF主要由AKI中的免疫细胞表达而非近端小管细胞,近端小管细胞TNF敲除不影响UUO的AKI-to-CKD转化。
核心结论
- TNF抑制或EGFR抑制同等减少小鼠AKI-to-CKD转化和纤维化约25%,联合无额外效果。
- 作者结论认为AKI期间或之后短期使用抗TNF生物制剂可能有助于预防AKI-to-CKD转化。
研究设计与样本
- 小鼠接受双侧肾缺血再灌注损伤或单侧输尿管梗阻(UUO)。
- 肾脏通过组织学、免疫组化、qPCR、western blot、质谱流式、scRNA测序和细胞因子谱分析。
主要发现
- TNF抑制或EGFR抑制均同等减少AKI-to-CKD转化和纤维化约25%,联合无额外效果。
- EGFR抑制使肾脏TNF表达降低约50%,主要减少早期AKI后肾脏中表达TNF的免疫细胞积聚。
- TNF抑制不影响EGFR活化或免疫细胞积聚。
- scRNAseq数据显示TNF主要由AKI中的免疫细胞表达而非近端小管细胞(PTC),PTC-TNF敲除不影响UUO的AKI-to-CKD转化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation is a key driver of the transition of acute kidney injury to progressive fibrosis and chronic kidney disease (AKI-to-CKD transition). Blocking a-disintegrin-and-metalloprotease-17 (ADAM17)-dependent ectodomain shedding, in particular of epidermal growth factor receptor (EGFR) ligands and of the type 1 inflammatory cytokine tumor necrosis factor (TNF), reduces pro-inflammatory and pro-fibrotic responses after ischemic AKI or unilateral ureteral obstruction (UUO), a classical fibrosis model. Metalloprotease or EGFR inhibition show significant undesirable side effects in humans. In retrospective studies anti-TNF biologics reduce the incidence and progression of CKD in humans. Whether TNF has a role in AKI-to-CKD transition and how TNF inhibition compares to EGFR inhibition is largely unknown. METHODS: Mice were subjected to bilateral renal ischemia-reperfusion injury or unilateral ureteral obstruction. Kidneys were analyzed by histology, immunohistochemistry, qPCR, western blot, mass cytometry, scRNA sequencing, and cytokine profiling. RESULTS: Here we show that TNF or EGFR inhibition reduce AKI-to-CKD transition and fibrosis equally by about 25%, while combination has no additional effect. EGFR inhibition reduced kidney TNF expression by about 50% largely by reducing accumulation of TNF expressing immune cells in the kidney early after AKI, while TNF inhibition did not affect EGFR activation or immune cell accumulation. Using scRNAseq data we show that TNF is predominantly expressed by immune cells in AKI but not in proximal tubule cells (PTC), and PTC-TNF knockout did not affect AKI-to-CKD transition in UUO. Thus, the anti-inflammatory and anti-fibrotic effects of the anti-TNF biologic etanercept in AKI-to-CKD transition rely on blocking TNF that is released from immune cells recruited or accumulating in response to PTC-EGFR signals. CONCLUSION: Short-term anti-TNF biologics during or after AKI could be helpful in the prevention of AKI-to-CKD transition.
引用
- Abdelmageed MM, Kefaloyianni E, Arthanarisami A, et al. TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment. Nephrol Dial Transplant. 2023. PMID: 36269313. doi:10.1093/ndt/gfac290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。